CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it will be presenting updated progression-free survival and overall survival results from its completed Phase 1b/2 clinical trial of aldoxorubicin in soft tissue sarcoma.
http://ift.tt/1mQrKli
http://ift.tt/1mQrKli
No comments:
Post a Comment